← Eichor
Condition: First In Man Study To Evaluate Initial Safety Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: First In Man Study To Evaluate Initial Safety

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
Phase 1 · 1 location(s) · Vaxcyte, Inc. · NCT07616934First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT07265622A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1 · 19 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06859762A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of
Phase 1/Phase 2 · 12 location(s) · Ipsen · NCT07213817FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Phase 1 · 5 location(s) · Pfizer · NCT06564389First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
Phase 1 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07169318A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07197827Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961Feasibility Study to Evaluate the Safety of the Autologous GrOwnValve Transcatheter Pulmonary Heart Valve
NA · 1 location(s) · Charite University, Berlin, Germany · NCT05809856A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/Phase 2 · 1 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT04686682First-in-human Study of HSK56630 in Healthy Subjects
Phase 1 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07580794A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · Chong Kun Dang Pharmaceutical · NCT07439094Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia
Phase 1/Phase 2 · 4 location(s) · Absci Pty Ltd. · NCT07317544A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Phase 1/Phase 2 · 6 location(s) · Carrick Therapeutics Limited · NCT06600789Healthy Participants Randomized, Double-blind, Placebo-controlled, Phase Ⅰ
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07640438A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Phase 1 · 12 location(s) · BioCryst Pharmaceuticals · NCT06539507A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Phase 1/Phase 2 · 5 location(s) · Arrowhead Pharmaceuticals · NCT06700538First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Phase 1/Phase 2 · 8 location(s) · AstraZeneca · NCT07529717A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio
Phase 1 · 1 location(s) · Debiopharm International SA · NCT07035769A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 10 location(s) · Flare Therapeutics Inc. · NCT07719361Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Phase 1 · 3 location(s) · Sound Biopharmaceuticals Ltd. · NCT06410092A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Phase 1 · 10 location(s) · Eli Lilly and Company · NCT06297590Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 10 location(s) · InSilico Medicine Hong Kong Limited · NCT06414460Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Phase 1/Phase 2 · 8 location(s) · Adcendo ApS · NCT06797999A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk
Phase 1 · 8 location(s) · GluBio Therapeutics Inc. · NCT06146257An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability,
Phase 1/Phase 2 · 2 location(s) · Shanghai SciBrunch Therapeutics Co., Ltd. · NCT07359066
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.